This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Will Pfizer's (PFE) Stock Keep Up the Momentum in 2019?
by Zacks Equity Research
Pfizer (PFE) performs better than the industry in 2018 and looks well poised to keep the positive momentum alive in 2019.
Pfizer (PFE) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Pfizer (PFE) closed the most recent trading day at $42.97, moving +0.28% from the previous trading session.
Conatus (CNAT) Focuses on Developing NASH Candidate Emricasan
by Zacks Equity Research
Conatus (CNAT) concentrates on the development of its lead candidate emricasan for treating patients with fibrosis or cirrhosis caused by NASH.
Will AbbVie (ABBV) Shares Regain Lost Momentum in 2019?
by Zacks Equity Research
Though AbbVie's (ABBV) stock was down this year, it looks well poised for a recovery in 2019.
Pfizer/Merck KGaA End Bavencio Ovarian Cancer Phase III Study
by Zacks Equity Research
Pfizer (PFE) and Merck KGaA terminate a late-stage study on Bavencio. This is the second ovarian cancer study failure in less than two months.
AbbVie (ABBV) Seeks Approval for RA Candidate Upadacitinib
by Zacks Equity Research
AbbVie (ABBV) submits regulatory applications in the United States and EU for upadacitinib, for the treatment of adult patients with moderate to severe rheumatoid arthritis.
Pfizer Xtandi Succeeds in Late-Stage Prostate Cancer Study
by Zacks Equity Research
Pfizer's (PFE) prostate cancer drug, Xtandi, met the primary endpoint in a late-stage study that can expand the label of the drug to include hormone-sensitive patients.
Pharma Stock Roundup: GSK, PFE Ink Consumer Health JV, JNJ Hit by Talc Allegations
by Zacks Equity Research
Glaxo (GSK) and Pfizer (PFE) agree to merge their consumer healthcare units into a new JV. J&J stock hit by reports alleging it of being aware of the presence of asbestos in baby powder.
Company News For Dec 20, 2018
by Zacks Equity Research
Companies In The News Are: FDX,GIS,LLY,PFE,GSK
Glaxo, Pfizer to Merge Consumer Health Units, Form New JV
by Zacks Equity Research
Glaxo (GSK) and Pfizer agree to merge their consumer healthcare units into a new joint venture (JV) with almost $13 billion in annual sales. Glaxo will eventually spin-off the joint venture.
Do Options Traders Know Something About Pfizer (PFE) Stock We Don't?
by Zacks Equity Research
Investors need to pay close attention to Pfizer (PFE) stock based on the movements in the options market lately.
The Zacks Analyst Blog Highlights: Walmart, Pfizer, Adobe, Johnson & Johnson and IBM
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Walmart, Pfizer, Adobe, Johnson & Johnson and IBM
Top Research Reports for Walmart, Pfizer & Adobe
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Walmart (WMT), Pfizer (PFE) and Adobe (ADBE).
Pfizer (PFE) Stock Moves -1.58%: What You Should Know
by Zacks Equity Research
In the latest trading session, Pfizer (PFE) closed at $43.11, marking a -1.58% move from the previous day.
Pfizer's (PFE) Biosimilar of Avastin Gets Positive CHMP Nod
by Zacks Equity Research
Pfizer (PFE) gets positive CHMP opinion for Zirabev (bevacizumab), a potential biosimilar to Roche's Avastin (bevacizumab).
Lilly (LLY) to Acquire Pain Candidate From Private Biotech
by Zacks Equity Research
Lilly (LLY) inks a deal with privately held Hydra Biosciences to add the latter's pre-clinical pain candidate to its portfolio.
Should You Invest in the VanEck Vectors Pharmaceutical ETF (PPH)?
by Sweta Killa
Sector ETF report for PPH
Pharma Stock Roundup: AZN, RHHBY Cancer Drugs, LLY, BMY New Deals in Focus
by Zacks Equity Research
AstraZeneca's (AZN) Imfinzi misses endpoint in study. Roche's (RHHBY) cancer drug combo gets FDA nod for first-line lung cancer. Lilly (LLY) & Bristol Myers (BMY) sign new deals.
Is Franklin LibertyQ U.S. Equity ETF (FLQL) a Strong ETF Right Now?
by Sweta Killa
Smart Beta ETF report for FLQL
Pfizer's (PFE) Shares Drop on Rating Downgrade by JP Morgan
by Zacks Equity Research
JP Morgan downgrades Pfizer (PFE) on assumptions that the market has discounted all growth factors for Pfizer.
Pfizer (PFE) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Pfizer (PFE) closed at $44.40, marking a +1.09% move from the previous day.
Pharma Stock Roundup: Glaxo's TESARO Buyout & Horlicks Sale, ASH Cancer Data Updates
by Zacks Equity Research
Glaxo (GSK) to buy TESARO and divest Horlicks brand to Unilever. ASH cancer presentations grab headilines.
Conatus' Emricasan Misses Primary Endpoint in Mid-Stage Study
by Zacks Equity Research
Conatus' (CNAT) emricasan fails to meet the primary endpoint in a phase IIb study on compensated NASH cirrhosis patients at high risk of decompensation.
Exelixis Initiates Pivotal Liver Cancer Study on Cabometyx
by Zacks Equity Research
Exelixis (EXEL) and its partner announce initiation of a pivotal study to evaluate its kidney cancer drug, Cabometyx, in combination with Roche's Tecentriq in liver cancer.
Pfizer (PFE) Stock Moves -1.78%: What You Should Know
by Zacks Equity Research
Pfizer (PFE) closed the most recent trading day at $45.17, moving -1.78% from the previous trading session.